New medicines are urgently required to treat the fatal neuromuscular disease Duchenne muscular dystrophy (DMD). Dimethyl fumarate (DMF) is a potent...
Array
(
[id_prestablog_news] => 1893
[id_shop] => 1
[date] => 2023-11-08 00:00:00
[date_modification] => 2024-02-09 14:15:13
[langues] => ["1","2"]
[actif] => 1
[slide] => 0
[url_redirect] =>
[average_rating] =>
[number_rating] =>
[author_id] => 1
[featured] => 0
[prim_key] => 3450
[id_lang] => 1
[title] => Dimethyl fumarate modulates the dystrophic disease program following short-term
[paragraph] => Dimethyl fumarate modulates the dystrophic disease program following short-term treatment
[content] => Authors
itenis EJ, Sahakian L, Debrincat D, Stupka N, Hafner P, Arthur PG, Terrill JR, Apostolopoulos V, de Haan JB, Guven N, Fischer D, Rybalka E.
Lab
Victoria University, Melbourne, Victoria, Australia
Journal
JCI Insight
Abstract
New medicines are urgently required to treat the fatal neuromuscular disease Duchenne muscular dystrophy (DMD). Dimethyl fumarate (DMF) is a potent immunomodulatory small molecule nuclear erythroid 2-related factor 2 activator with current clinical utility in the treatment of multiple sclerosis and psoriasis that could be effective for DMD and rapidly translatable. Here, we tested 2 weeks of daily 100 mg/kg DMF versus 5 mg/kg standard-care prednisone (PRED) treatment in juvenile mdx mice with early symptomatic DMD. Both drugs modulated seed genes driving the DMD disease program and improved force production in fast-twitch muscle. However, only DMF showed pro-mitochondrial effects, protected contracting muscles from fatigue, improved histopathology, and augmented clinically compatible muscle function tests. DMF may be a more selective modulator of the DMD disease program than PRED, warranting follow-up longitudinal studies to evaluate disease-modifying impact.
BIOSEB Instruments Used
Grip strength test (BIO-GS4)
[meta_description] =>
[meta_keywords] => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721277/
[meta_title] =>
[link_rewrite] => dimethyl-fumarate-modulates-the-dystrophic-disease-program-following-short-term-treatment
[actif_langue] => 1
[read] => 648
[count_comments] => 0
[id] => 1893
[categories] => Array
(
[44] => Array
(
[id_prestablog_categorie] => 44
[title] => Duchenne muscular dystrophy
[link_rewrite] => Duchenne-muscular-dystrophy
)
[2] => Array
(
[id_prestablog_categorie] => 2
[title] => Publications
[link_rewrite] => publications
)
)
[authors] =>
[paragraph_crop] => Dimethyl fumarate modulates the dystrophic disease program following short-term treatment
[link_for_unique] => 1
[products_liaison] => Array
(
[48] => Array
(
[name] => Grip strength test
[description_short] => An easy way to objectively quantify the muscular strength of mice and rats, and to assess the effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration. It is widely used in conjunction with the ROTAROD motor coordination test: a normally coordinated rodent will show a decreased latency to fall off the rotating rod if its muscular strength is low. The Grip Strength Test is a must for your research on activity, motor control & coordination, and is particularly well suited for studies on Parkinson's & Huntington's disease.
New features GS4 - 2023: Color display with permanent backlight screen for easier reading, reset by footswitch, Improved battery time, Larger data memory of 500 values, Animal counter, USB port (charging/data transfer)


[thumb] =>
[img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
[image_presente] => 1
[link] => https://bioseb.com/en/activity-motor-control-coordination/48-grip-strength-test.html
)
)
)
1 Read more